Marburg virus

Source: Wikipedia, the free encyclopedia.
For the genus, see Marburgvirus.
Marburg virus
Transmission electron micrograph of Marburg virus
Transmission electron micrograph
of Marburg virus
Virus classification Edit this classification
(unranked): Virus
Realm: Riboviria
Kingdom: Orthornavirae
Phylum:
Negarnaviricota
Class: Monjiviricetes
Order: Mononegavirales
Family: Filoviridae
Genus: Marburgvirus
Species:
Marburg marburgvirus
Virus:
Marburg virus

Marburg virus (MARV) is a

Marburg marburgvirus, genus Marburgvirus.[1] It causes Marburg virus disease in primates, a form of viral hemorrhagic fever.[2] The virus is considered to be extremely dangerous. The World Health Organization (WHO) rates it as a Risk Group 4 Pathogen (requiring biosafety level 4-equivalent containment).[3] In the United States, the National Institute of Allergy and Infectious Diseases ranks it as a Category A Priority Pathogen[4] and the Centers for Disease Control and Prevention lists it as a Category A Bioterrorism Agent.[5] It is also listed as a biological agent for export control by the Australia Group.[6]

The virus can be transmitted by exposure to one species of

haemorrhage, fever, and other symptoms similar to Ebola, which belongs to the same family of viruses. According to the WHO, there are no approved vaccines or antiviral treatment for Marburg, but early, professional treatment of symptoms like dehydration considerably increases survival chances.[7]

In 2009, expanded clinical trials of an Ebola and Marburg vaccine began in Kampala, Uganda.[8][9]

History

Discovery

See also:
1967 Marburg virus outbreak
EMDB entry.[10][11]

Marburg virus was first described in 1967.[12] It was discovered that year during a set of outbreaks of Marburg virus disease in the German cities of Marburg and Frankfurt and the Yugoslav capital Belgrade. Laboratory workers were exposed to tissues of infected grivet monkeys (the African green monkey, Chlorocebus aethiops) at the Behringwerke, a major industrial plant in Marburg which was then part of Hoechst, and later part of CSL Behring. During the outbreaks, thirty-one people became infected and seven of them died.[13]

Nomenclature

The virus is one of two members of the species

Marburg marburgvirus, which is included in the genus Marburgvirus, family Filoviridae, and order Mononegavirales. The name Marburg virus is derived from Marburg (the city in Hesse, Germany, where the virus was first discovered) and the taxonomic suffix virus.[1]

Marburg virus was first introduced under this name in 1967.[12] The virus name was changed to Lake Victoria marburgvirus in 2005, confusingly making the only difference in distinguishing between a Marburg virus organism and its species as a whole italicization, as in Lake Victoria marburgvirus.[14][15][16] Still, most scientific articles continued to use the name Marburg virus. Consequently, in 2010, the name Marburg virus was reinstated and the species name changed.[1]

Virology

Genome

Marburg virion and genome

Like all

5' cap, are not polyadenylated, and are not covalently linked to a protein.[17] Marburgvirus genomes are approximately 19 kbp long and contain seven genes in the order 3'-UTR-NP-VP35-VP40-GP-VP30-VP24-L-5'-UTR.[18]

Structure

Micrograph of the Marburg viruses
Colorized electron micrograph of a Marburg virus

Like all

width, but vary somewhat in length. In general, the median particle length of marburgviruses ranges from 795 to 828 nm (in contrast to ebolavirions, whose median particle length was measured to be 974–1,086 nm), but particles as long as 14,000 nm have been detected in tissue culture.[19]

Marburgvirions consist of seven structural proteins. At the center is the

ribonucleocapsid, which consists of the genomic RNA wrapped around a polymer of nucleoproteins (NP). Associated with the ribonucleoprotein is the RNA-dependent RNA polymerase (L) with the polymerase cofactor (VP35) and a transcription activator (VP30). The ribonucleoprotein is embedded in a matrix, formed by the major (VP40) and minor (VP24) matrix proteins. These particles are surrounded by a lipid membrane derived from the host cell membrane. The membrane anchors a glycoprotein (GP1,2) that projects 7 to 10 nm spikes away from its surface. While nearly identical to ebolavirions in structure, marburgvirions are antigenically distinct.[20]

Entry

filovirus entry because it mediates infection by binding directly to the viral envelope glycoprotein[22] and that the second lysosomal domain of NPC1 mediates this binding.[23]

In one of the original studies, a small molecule was shown to inhibit Ebola virus infection by preventing the virus glycoprotein from binding to NPC1.[22][24] In the other study, mice that were heterozygous for NPC1 were shown to be protected from lethal challenge with mouse-adapted Ebola virus.[21]

Replication

The Marburg virus replication cycle

The Marburg virus

nucleocapsid into the cytosol.[citation needed
]

The

promoter located at the 3' end of the genome. Transcription either terminates after a gene or continues to the next gene downstream. This means that genes close to the 3' end of the genome are transcribed in the greatest abundance, whereas those toward the 5' end are least likely to be transcribed. The gene order is therefore a simple but effective form of transcriptional regulation.[25]

The most abundant protein produced is the nucleoprotein, whose concentration in the cell determines when L switches from gene transcription to genome replication. Replication results in full-length, positive-stranded antigenomes that are in turn transcribed into negative-stranded virus progeny genome copies. Newly synthesized structural proteins and genomes self-assemble and accumulate near the inside of the cell membrane. Virions bud off from the cell, gaining their envelopes from the cellular membrane they bud from. The mature progeny particles then infect other cells to repeat the cycle.[14]

Ecology

The geographic distribution of Marburg virus and Egyptian fruit bats

In 2009, the successful isolation of infectious MARV was reported from caught healthy

RAVV,[26] strongly suggests that Old World fruit bats are involved in the natural maintenance of marburgviruses. Further studies are necessary to establish whether Egyptian rousettes are the actual hosts of MARV and RAVV or whether they get infected via contact with another animal and therefore serve only as intermediate hosts. In 2012 the first experimental infection study of Rousettus aegyptiacus with MARV provided further insight into the possible involvement of these bats in MARV ecology.[27]

Experimentally infected bats developed relatively low viremia lasting at least five days, but remained healthy and did not develop any notable gross pathology. The virus also replicated to high titers in major organs (liver and spleen), and organs that might possibly be involved in virus transmission (lung, intestine, reproductive organs, salivary gland, kidney, bladder, and mammary gland). The relatively long period of viremia noted in this experiment could possibly also facilitate mechanical transmission by blood sucking arthropods in addition to infection of susceptible vertebrate hosts by direct contact with infected blood.[27]

Evolution

The viral strains fall into two clades: Ravn virus and Marburg virus.[28] The Marburg strains can be divided into two: A and B. The A strains were isolated from Uganda (five from 1967), Kenya (1980) and Angola (2004–2005) while the B strains were from the Democratic Republic of the Congo epidemic (1999–2000) and a group of Ugandan isolates isolated in 2007–2009.[25]

The mean evolutionary rate of the whole genome was 3.3 × 10−4 substitutions/site/year (credibility interval 2.0–4.8). The Marburg strains had a mean root time of the most recent common ancestor of 177.9 years ago (95% highest posterior density 87–284) suggesting an origin in the mid 19th century. In contrast, the Ravn strains origin dated back to a mean 33.8 years ago (the early 1980s). The most probable location of the Marburg virus ancestor was Uganda whereas that of the RAVV ancestor was Kenya.[citation needed]

Human disease

Main article: Marburg virus disease

MARV is one of two Marburg viruses that causes Marburg virus disease (MVD) in humans (in the literature also often referred to as Marburg hemorrhagic fever, MHF). The other one is Ravn virus (RAVV). Both viruses fulfill the criteria for being a member of the species Marburg marburgvirus because their genomes diverge from the prototype Marburg marburgvirus or the Marburg virus variant Musoke (MARV/Mus) by <10% at the nucleotide level.[1]

Recorded outbreaks

Year Geographic location Virus Human cases Human deaths Case fatality rate Notes
1967 Marburg and Frankfurt, West Germany, and Belgrade, Socialist Federal Republic of Yugoslavia MARV 31 7 23% Laboratory leak[29][12][30][31][32][33][34][35][36]
1975 Rhodesia and Johannesburg, South Africa MARV 3 1 33% [37][38][39]
1980 Kenya MARV 2 1 50% [40]
1987 Kenya RAVV 1 1 100% [41][42]
1988 Koltsovo, Soviet Union 1 1 100% Laboratory accident[43]
1990 Koltsovo, Soviet Union MARV 1 1 100% Laboratory accident[44]
1998–2000
Durba and Watsa, Democratic Republic of the Congo
 MARV & RAVV 154 128 83% Two different marburgviruses, MARV and Ravn virus (RAVV), cocirculated and caused disease. The number of cases and deaths due to MARV or RAVV infection have not been reported.[45][46][47]
2004–2005 Angola MARV 374 329 90% [48][49][50][51][52][53][54]
2007 Uganda MARV & RAVV 4 1 25% [26][55]
2008
The Netherlands
 MARV 1 1 100% [56]
2012 Uganda MARV 18 9 50% [57]
2014 Uganda MARV 1 1 100% [58][59]
2017 Uganda MARV 3 3 100% [60]
2021 Guinea MARV 1 1 100% The Guinean government detected the case from a sample of patients who died on August 2, 2021, in the southern prefecture of Gueckedou near the country's borders with Sierra Leone and Liberia.[61][62][63]
2022 Ghana MARV 4 3 75% Four cases have been reported so far with preparations for a possible outbreak being made. On 17 July 2022, two cases were confirmed by Ghana,[64] with two more being subsequently confirmed on 27 July 2022.[65]

See Ghana Marburg virus outbreak 2022.[66]

Feb 2023 Equatorial Guinea 25 11 44% See Equatorial Guinea Marburg virus outbreak 2023.[67][68]
Mar 2023 Tanzania 8 5 63% "Five dead as Tanzania detects first-ever Marburg virus outbreak". aljazeera. Retrieved 22 March 2023.

Prevention

The first clinical study testing the efficacy of a Marburg virus vaccine was conducted in 2014. The study tested a DNA vaccine and concluded that individuals inoculated with the vaccine exhibited some level of antibodies. However, these vaccines were not expected to provide definitive immunity.[69] Several animal models have shown to be effective in the research of Marburg virus, such as hamsters, mice, and non-human primates (NHPs). Mice are useful in the initial phases of vaccine development as they are ample models for mammalian disease, but their immune systems are still different enough from humans to warrant trials with other mammals.[70] Of these models, the infection in macaques seems to be the most similar to the effects in humans.[71] A variety of other vaccines have been considered. Virus replicon particles (VRPs) were shown to be effective in guinea pigs, but lost efficacy once tested on NHPs. Additionally, an inactivated virus vaccine proved ineffective. DNA vaccines showed some efficacy in NHPs, but all inoculated individuals showed signs of infection.[72]

Because Marburg virus and Ebola virus belong to the same family, Filoviridae, some scientists have attempted to create a single-injection vaccine for both viruses. This would both make the vaccine more practical and lower the cost for developing countries.[73] Using a single-injection vaccine has shown to not cause any adverse reactogenicity, which the possible immune response to vaccination, in comparison to two separate vaccinations.[69]

As of June 23, 2022, researchers working with the Public Health Agency of Canada conducted a study which showed promising results of a recombinant vesicular stomatitis virus (rVSV) vaccine in guinea pigs, entitled PHV01. According to the study, inoculation with the vaccine approximately one month prior to infection with the virus provided a high level of protection.[74]

Even though there is much experimental research on Marburg virus, there is still no prominent vaccine. Human vaccination trials are either ultimately unsuccessful or are missing data specifically regarding Marburg virus.[75] Due to the cost needed to handle Marburg virus at qualified facilities, the relatively few number of fatalities, and lack of commercial interest, the possibility of a vaccine has simply not come to fruition.[76]

Biological weapon

The

Sergiev Posad), the Scientific-Production Association "Vektor" (today the State Research Center of Virology and Biotechnology "Vektor") in Koltsovo, and the Irkutsk Scientific-Research Anti-Plague Institute of Siberia and the Far East in Irkutsk.[77]

As most performed research was highly

Stepnogorsk Scientific Experimental and Production Base in Stepnogorsk, Kazakh Soviet Socialist Republic (today Kazakhstan),[77] suggesting that the development of a MARV biological weapon had reached advanced stages. Independent confirmation for this claim is lacking. At least one laboratory accident with MARV, resulting in the death of Koltsovo researcher Nikolai Ustinov, occurred during the Cold War in the Soviet Union and was first described in detail by Alibek.[77]

MARV is a select agent under US law.[78]

References

  1. ^
    PMID 21046175
    .
  2. ^ Spickler A. "Ebolavirus and Marburgvirus Infections" (PDF).
  3. ^ US Department of Health and Human Services. "Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition". Retrieved 2011-10-16.
  4. ^ "Biodefense Category A, B, C Pathogens, NIAID, NIH". Archived from the original on 2011-10-22. Retrieved 2011-10-16.
  5. ^ US Centers for Disease Control and Prevention (CDC). "Bioterrorism Agents/Diseases". Archived from the original on 2014-07-22. Retrieved 2011-10-16.
  6. ^ The Australia Group. "List of Biological Agents for Export Control". Archived from the original on 2011-08-06. Retrieved 2011-10-16.
  7. ^ Marburg virus disease Fact sheet Updated October 2017 http://www.who.int/mediacentre/factsheets/fs_marburg/en/
  8. ^ Beth Skwarecki Ebola, Marburg DNA Vaccines Prove Safe in Phase 1 Trial Medscape Medical News, September 17, 2014
  9. U.S. Department of Health & Human Services
  10. ^ "CryoEM reconstruction of the Marburg virus nucleocapsid". Electron Microscopy Data Bank. Retrieved 18 February 2023.
  11. PMID 22110401
    .
  12. ^
    S2CID 116556454
    .
  13. PMID 17940940
    .
  14. ^
    ISBN 978-0-12-370200-5
    .
  15. S2CID 43887711
    .
  16. PMID 20204430
    .
  17. ISBN 978-0-12-370200-5
    .
  18. ^
    PMID 7118520
    .
  19. PMID 8837880
    .
  20. PMID 29940415
    .
  21. ^
    PMID 21866103
    .
  22. ^
    PMID 21866101
    .
  23. PMID 22395071
    .
  24. S2CID 26888076
    .
  25. ^
    PMID 23202446
    .
  26. ^
    PMID 19649327
    .
  27. ^
    PMID 23029039. Open access icon
  28. S2CID 1704025
    .
  29. PMID 32404328
    .
  30. PMID 4168558
    .
  31. S2CID 30252321
    .
  32. S2CID 260056835
    .
  33. S2CID 260058558
    .
  34. PMID 5005859
    .
  35. S2CID 12791113
    .
  36. ISBN 978-0-387-05199-4
    .
  37. PMID 811315
    .
  38. PMID 406394
    .
  39. PMID 569445
    .
  40. S2CID 42832324
    .
  41. ^ Marburg and Ebola viruses; Advances in Virus Research; Volume 47, 1996, Pages 1–52
  42. ^ "Outbreak Table | Marburg Hemorrhagic Fever | CDC". www.cdc.gov.
  43. S2CID 25789824
    .
  44. PMID 7941853
    .
  45. PMID 10546197
    .
  46. PMID 14720391
    .
  47. PMID 16943403
    .
  48. PMID 16038348
    .
  49. PMID 15917379
    .
  50. PMID 16775337
    .
  51. PMID 17940944
    .
  52. PMID 17940945
    .
  53. PMID 18838150
    .
  54. PMID 20441515
    .
  55. PMID 21987753
    .
  56. PMID 19751577
    .
  57. ^ "Marburg hemorrhagic fever outbreak continues in Uganda". October 2012.
  58. ^ "1st LD-Writethru: Deadly Marburg hemorrhagic fever breaks out in Uganda". October 5, 2014.
  59. ^ Ntale S (October 8, 2014). "99 in Uganda quarantined after Marburg virus death". CNN. Retrieved 2014-10-19.
  60. ^ "Marburg virus disease – Uganda Disease outbreak news". October 25, 2017. Archived from the original on October 26, 2017.
  61. ^ "Marburg virus disease - Guinea". www.who.int. Retrieved 2022-11-29.
  62. S2CID 250114159
    .
  63. S2CID 253371377. {{cite journal}}: Cite journal requires |journal= (help
    )
  64. ^ "Ghana confirms its first outbreak of highly infectious Marburg virus". Reuters. 2022-07-18. Retrieved 2022-07-18.
  65. ^ "WHO confirms two more Marburg virus cases in Ghana, says official". National Post. 2022-07-27. Retrieved 2022-07-27.
  66. ^ "Ghana prepares for possible first-ever Marburg virus outbreak". UN News. 2022-07-08. Retrieved 2022-07-18.
  67. ^ "Equatorial Guinea confirms first-ever Marburg virus disease outbreak". World Health Organization. 13 February 2023. Retrieved 13 February 2023.
  68. Barron's
    . Retrieved 28 February 2023.
  69. ^
    S2CID 205975536
    .
  70. PMID 31888676
    .
  71. PMID 27043611
    .
  72. PMID 31589088
    .
  73. PMID 19386702
    .
  74. PMID 35891170
    .
  75. S2CID 229178658
    .
  76. PMID 28447193
    .
  77. ^
    ISBN 978-0-385-33496-9
    .
  78. ^ US Animal and Plant Health Inspection Service (APHIS) and US Centers for Disease Control and Prevention (CDC). "National Select Agent Registry (NSAR)". Retrieved 2011-10-16.

Further reading

External links

Wikimedia Commons has media related to Marburgvirus.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Marburg_virus&oldid=1222470996"